Galecto (GLTO) Competitors $5.84 +0.03 (+0.52%) (As of 10:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLTO vs. LMNL, RNXT, SRZN, ALTS, BIVI, LTRN, BLRX, HCWB, CTXR, and KALAShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Liminal BioSciences (LMNL), RenovoRx (RNXT), Surrozen (SRZN), Janone (ALTS), BioVie (BIVI), Lantern Pharma (LTRN), BioLineRx (BLRX), HCW Biologics (HCWB), Citius Pharmaceuticals (CTXR), and KALA BIO (KALA). Galecto vs. Liminal BioSciences RenovoRx Surrozen Janone BioVie Lantern Pharma BioLineRx HCW Biologics Citius Pharmaceuticals KALA BIO Galecto (NASDAQ:GLTO) and Liminal BioSciences (NASDAQ:LMNL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Is GLTO or LMNL more profitable? Liminal BioSciences has a net margin of 248.35% compared to Galecto's net margin of 0.00%. Galecto's return on equity of -76.96% beat Liminal BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -76.96% -66.59% Liminal BioSciences 248.35%-88.44%-64.15% Does the MarketBeat Community believe in GLTO or LMNL? Galecto received 18 more outperform votes than Liminal BioSciences when rated by MarketBeat users. Likewise, 60.38% of users gave Galecto an outperform vote while only 48.28% of users gave Liminal BioSciences an outperform vote. CompanyUnderperformOutperformGalectoOutperform Votes3260.38% Underperform Votes2139.62% Liminal BioSciencesOutperform Votes1448.28% Underperform Votes1551.72% Do analysts recommend GLTO or LMNL? Galecto currently has a consensus price target of $10.00, indicating a potential upside of 72.12%. Given Galecto's stronger consensus rating and higher possible upside, research analysts plainly believe Galecto is more favorable than Liminal BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Liminal BioSciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, GLTO or LMNL? Liminal BioSciences has higher revenue and earnings than Galecto. Galecto is trading at a lower price-to-earnings ratio than Liminal BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$38.35M-$19.14-0.30Liminal BioSciences$310K85.00$380K$0.2929.31 Does the media refer more to GLTO or LMNL? In the previous week, Galecto had 2 more articles in the media than Liminal BioSciences. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Liminal BioSciences. Galecto's average media sentiment score of 0.58 beat Liminal BioSciences' score of 0.00 indicating that Galecto is being referred to more favorably in the media. Company Overall Sentiment Galecto Positive Liminal BioSciences Neutral Which has more volatility and risk, GLTO or LMNL? Galecto has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Liminal BioSciences has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Do insiders and institutionals hold more shares of GLTO or LMNL? 14.2% of Galecto shares are owned by institutional investors. Comparatively, 0.7% of Liminal BioSciences shares are owned by institutional investors. 11.9% of Galecto shares are owned by insiders. Comparatively, 2.2% of Liminal BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryGalecto beats Liminal BioSciences on 11 of the 17 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.65M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-0.3010.78130.5317.82Price / SalesN/A243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book0.195.474.684.68Net Income-$38.35M$153.61M$119.23M$226.08M7 Day Performance-14.81%-2.00%-1.83%-1.04%1 Month Performance-17.35%-7.46%-3.61%1.04%1 Year Performance-58.87%31.82%31.74%26.28% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.1146 of 5 stars$5.84+0.5%$10.00+71.2%-60.6%$7.71MN/A-0.3140Gap UpLMNLLiminal BioSciencesN/A$8.50+0.1%N/A+0.0%$26.35M$310,000.0029.31251RNXTRenovoRx2.6223 of 5 stars$1.27+6.7%$6.13+382.3%+98.7%$30.48MN/A-2.126News CoveragePositive NewsSRZNSurrozen1.4586 of 5 stars$9.32+4.7%N/A+25.6%$30.29M$12.50M0.0042Gap UpALTSJanone1.2188 of 5 stars$2.15-1.8%N/AN/A$30.25M$39.61M0.00170BIVIBioVie0.625 of 5 stars$3.23-3.9%$4.00+23.8%-24.0%$30.14MN/A0.0010LTRNLantern Pharma1.0942 of 5 stars$2.79-5.1%N/A-27.0%$30.08MN/A0.0020Positive NewsBLRXBioLineRx1.9751 of 5 stars$0.37-31.8%$21.00+5,545.2%-67.9%$29.74M$4.80M0.0040News CoverageGap DownHigh Trading VolumeHCWBHCW Biologics1.1093 of 5 stars$0.78-17.3%N/A-12.3%$29.63M$2.84M0.0040Gap DownCTXRCitius Pharmaceuticals3.1588 of 5 stars$0.16-3.9%$4.00+2,351.0%-77.9%$29.50MN/A-0.7120Short Interest ↓KALAKALA BIO4.0824 of 5 stars$6.20-3.6%$15.00+141.9%+7.8%$28.58M$3.89M0.0030 Related Companies and Tools Related Companies Liminal BioSciences Competitors RenovoRx Competitors Surrozen Competitors Janone Competitors BioVie Competitors Lantern Pharma Competitors BioLineRx Competitors HCW Biologics Competitors Citius Pharmaceuticals Competitors KALA BIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLTO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLTO Stock Alerts